公开(公告)号：US20220362255A1

公开(公告)日：2022-11-17

申请号：US17725398

申请日：2022-04-20

Applicant: Celgene Corporation ,  Bristol-Myers Squibb Company

Inventor： Tonia J. Buchholz ,  Michael Pourdehnad ,  Poliana Alves Patah ,  Fan Wu

IPC: A61K31/5377 ,  A61K45/06

Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.

公开(公告)号：US20210113576A1

公开(公告)日：2021-04-22

申请号：US17075496

申请日：2020-10-20

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Henry Chang ,  Ellen Filvaroff ,  Shailaja Kasibhatla ,  Antonia Lopez-Girona ,  Adithi Mohan ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: A61K31/5377 ,  A61P35/04 ,  A61K45/06

Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

公开(公告)号：US20230277548A1

公开(公告)日：2023-09-07

申请号：US18315404

申请日：2023-05-10

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Shailaja Kasibhatla ,  Antonia Lopez-Girona ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: A61K31/5377

CPC classification number: A61K31/5377 ,  A61K9/0053

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

公开(公告)号：US20220324855A1

公开(公告)日：2022-10-13

申请号：US17848976

申请日：2022-06-24

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Antonia Lopez-Girona ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: C07D413/14 ,  A61P35/00 ,  C07K16/28

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.

公开(公告)号：US20190030018A1

公开(公告)日：2019-01-31

申请号：US16024581

申请日：2018-06-29

Applicant: Celgene Corporation

Inventor： Tonia J. Buchholz ,  James Carmichael ,  Soraya Carrancio ,  Jinhong Fan ,  Rajan Gupta ,  Gang Lu ,  Kyle MacBeth ,  Emily Pace ,  Daniel Pierce ,  Michael Pourdehnad ,  Yu Pu ,  Peng Wang ,  Naijun Wu ,  Sheena Yao

IPC: A61K31/454 ,  A61K47/40 ,  A61K9/00 ,  A61K45/06 ,  A61K31/436 ,  A61K9/19 ,  A61P35/02

Abstract: Provided herein are formulations and methods of use of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

公开(公告)号：US12178822B2

公开(公告)日：2024-12-31

申请号：US18315404

申请日：2023-05-10

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Shailaja Kasibhatla ,  Antonia Lopez-Girona ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: A61K31/5377 ,  A61K9/00

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

公开(公告)号：US11583536B2

公开(公告)日：2023-02-21

申请号：US17075496

申请日：2020-10-20

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Henry Chang ,  Ellen Filvaroff ,  Shailaja Kasibhatla ,  Antonia Lopez-Girona ,  Adithi Mohan ,  Rama Krishna Narla ,  Michael Pourdehnad ,  William Edward Pierceall ,  Anjan Guha Thakurta

IPC: A61K31/5377 ,  A61P35/04 ,  A61K45/06

Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

公开(公告)号：US20210113577A1

公开(公告)日：2021-04-22

申请号：US17075523

申请日：2020-10-20

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Shailaja Kasibhatla ,  Antonia Lopez-Girona ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: A61K31/5377

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

公开(公告)号：US20250017941A1

公开(公告)日：2025-01-16

申请号：US18901764

申请日：2024-09-30

Applicant: Celgene Corporation ,  Bristol-Myers Squibb Company

Inventor： Tonia J. Buchholz ,  Michael Pourdehnad ,  Poliana Alves Patah ,  Fan Wu

IPC: A61K31/5377 ,  A61K45/06

Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.

公开(公告)号：US20240400548A1

公开(公告)日：2024-12-05

申请号：US18799483

申请日：2024-08-09

Applicant: Celgene Corporation

Inventor： Maria Soraya Carrancio Anton ,  Tonia J. Buchholz ,  Antonia Lopez-Girona ,  Rama Krishna Narla ,  Michael Pourdehnad

IPC: C07D413/14 ,  A61K9/00 ,  A61P35/00 ,  C07K16/28

Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.